Dechra Pharmaceuticals Stock

Dechra Pharmaceuticals Dividend 2024

Dechra Pharmaceuticals Dividend

0.25 GBP

Dechra Pharmaceuticals Dividend yield

0.65 %

Ticker

DPH.L

ISIN

GB0009633180

WKN

578968

How much dividend does Dechra Pharmaceuticals 2024 pay?

According to the latest status from November 2024, Dechra Pharmaceuticals paid a total of 0.25 GBP per share in dividends within the last 12 months. With the current Dechra Pharmaceuticals price of 38.66 GBP, this corresponds to a dividend yield of 0.65 %. A dividend is paid times per year.

0.65 % Dividend Yield=
0.25 GBP Dividend
38.66 GBP Stock Price

Historical Dechra Pharmaceuticals Dividends

A dividend is paid times per year. Last year, the payout months were and April.

PaydateDividend
4/9/20230.13
11/27/20220.33
4/3/20220.12
11/28/20210.29
4/4/20210.11
12/5/20200.24
4/5/20200.1
11/24/20190.22
4/7/20190.1
11/25/20180.18
4/8/20180.07
11/26/20170.15
4/9/20170.06
11/27/20160.13
4/10/20160.06
11/29/20150.13
4/12/20150.06
12/6/20140.12
4/12/20140.05
12/6/20130.11
1
2
3

Dechra Pharmaceuticals dividend history and estimates

In 2023, Dechra Pharmaceuticals paid a dividend amounting to 0.25 GBP. Dividend means that Dechra Pharmaceuticals distributes a portion of its profits to its owners.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details

Dividend

Dividend Overview

The dividend per year chart for Dechra Pharmaceuticals provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify Dechra Pharmaceuticals’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating Dechra Pharmaceuticals's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

Dechra Pharmaceuticals Dividend History

DateDechra Pharmaceuticals Dividend
2028e0.25 undefined
2027e0.25 undefined
2026e0.25 undefined
2025e0.25 undefined
2024e0.25 undefined
20230.25 undefined
20220.45 undefined
20210.41 undefined
20200.34 undefined
20190.32 undefined
20180.26 undefined
20170.21 undefined
20160.18 undefined
20150.19 undefined
20140.17 undefined
20130.16 undefined
20120.14 undefined
20110.12 undefined
20100.11 undefined
20090.09 undefined
20080.08 undefined
20070.07 undefined
20060.06 undefined
20050.05 undefined
20040.05 undefined

Is the Dechra Pharmaceuticals Dividend Safe?

Dechra Pharmaceuticals has been increasing the dividend for 7 years.

Over the past 10 years, Dechra Pharmaceuticals has increased it by an annual 4.859 %.

Over a five-year period, the distribution increased by -0.395%.

Analysts expect a Dividend Increase of 0.688% for the current fiscal year.

Dechra Pharmaceuticals dividend payout ratio

In 2023, Dechra Pharmaceuticals had a payout ratio of 89.11%. The payout ratio indicates the percentage of the company's profits that Dechra Pharmaceuticals distributes as dividends.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Payout ratio
Details

Payout ratio

What is Yearly Payout Ratio?

The yearly payout ratio for Dechra Pharmaceuticals represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for Dechra Pharmaceuticals could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate Dechra Pharmaceuticals's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

Dechra Pharmaceuticals Payout Ratio History

DateDechra Pharmaceuticals Payout ratio
2028e85.86 %
2027e85.44 %
2026e86.36 %
2025e85.78 %
2024e84.18 %
202389.11 %
202284.06 %
202179.36 %
2020103.91 %
2019105.33 %
201868.92 %
201776.77 %
2016131.16 %
201585.6 %
201425.54 %
201377.78 %
201284.84 %
201160.93 %
201058.75 %
200957.28 %
200863.92 %
200749.46 %
200647.48 %
200546.76 %
200451.66 %

Dividend Details

Understanding Dechra Pharmaceuticals's Dividend Distributions

Dechra Pharmaceuticals’s dividends are a portion of the company’s profits distributed to shareholders. It is a critical indicator of the company’s financial health and attractiveness to investors. Dividends provide investors with a steady income stream, in addition to any profits that may come from selling the stock at a higher price than the purchase price.

Year-to-Year Comparison

Examining Dechra Pharmaceuticals's dividend distributions over the years can highlight the company’s profitability and stability. A consistent or increasing dividend payout can indicate a financially healthy company with predictable earnings, while fluctuations or reductions in dividends can suggest underlying financial or operational challenges.

Impact on Investments

Dechra Pharmaceuticals's dividend payments are an essential factor for income-focused investors. A robust dividend payout can enhance the stock’s appeal, offering regular income in addition to potential capital gains. It also can indicate the company's confidence in its future earnings, making it a significant consideration in investment decisions.

Interpreting Dividend Fluctuations

Changes in Dechra Pharmaceuticals’s dividends can result from shifts in the company’s earnings, financial policies, or reinvestment strategies. An increase in dividends often signals financial stability, while a decrease may indicate a need to conserve cash or reinvest profits to fuel growth, each scenario having different implications for investors.

Dechra Pharmaceuticals Aktienanalyse

What does Dechra Pharmaceuticals do?

Dechra Pharmaceuticals PLC is a British company specializing in animal medicine. It was founded in 1997 and has experienced remarkable growth since then. Dechra is listed on the London Stock Exchange and has its headquarters in Northwich, Cheshire, UK. Dechra builds its business models on a broad portfolio of products and services. The company is primarily focused on the development and sale of pharmaceuticals and diagnostics tailored to the needs of veterinarians and pet owners. The company has an extensive range of animal medicines, divided into categories such as antibiotics, painkillers, and anti-inflammatory drugs. Dechra operates three major business segments that drive its growth: the veterinary medicines business, the diagnostics business, and the specialty pharma business. The veterinary medicines business is the core of Dechra's operations. Here, the company produces products that can be used on livestock and companion animals. Dechra dominates the animal medicine market in Europe and has also established itself in the field of animal health in the US. The diagnostics business is another important segment that focuses on diagnostics and tests to quickly and effectively diagnose animal diseases. These products are primarily sold to veterinarians and veterinary laboratories. Dechra's specialty pharma business focuses on the production of specialty drugs tailored to a specific animal species or a specific disease that affects rarer species. Producing such medications generally requires higher expertise and also results in higher profitability due to typically lower competition. In recent years, Dechra has accelerated its presence and growth through targeted acquisitions. These acquisitions have expanded both Dechra's portfolio and geographic reach. In 2014, Dechra acquired US-based Genera N.A., a specialized pharmaceutical company producing animal medicines. With the acquisition of Genera, Dechra was able to strengthen its presence in the US animal medicine market. The company has also made acquisitions in Europe, such as the acquisition of Eurovet Animal Health in 2020. Eurovet is a Netherlands-based company specializing in animal health products and covers important market regions in Europe. The acquisition of Eurovet has allowed Dechra to strengthen its presence in Germany and Scandinavia. In summary, Dechra Pharmaceuticals PLC is one of the leading companies in the animal medicine industry. The company has maintained its reputation by creating innovative products and services based on the highest manufacturing and operational standards. The company is committed to continuing to provide value to veterinarians and pet owners while improving the health and well-being of animals. Dechra Pharmaceuticals is one of the most popular companies on Eulerpool.com.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Dechra Pharmaceuticals stock can be added to a savings plan with the following providers: Trade Republic

Frequently Asked Questions about Dechra Pharmaceuticals stock

How much dividend does Dechra Pharmaceuticals pay?

Over the past 12 months, Dechra Pharmaceuticals paid a dividend of 0.25 GBP . This corresponds to a dividend yield of about 0.65 %. For the coming 12 months, Dechra Pharmaceuticals is expected to pay a dividend of 0.25 GBP.

What is the dividend yield of Dechra Pharmaceuticals?

The current dividend yield of Dechra Pharmaceuticals is 0.65 %.

When does Dechra Pharmaceuticals pay dividends?

Dechra Pharmaceuticals pays a quarterly dividend. This is distributed in the months of November, April, November, April.

How secure is the dividend of Dechra Pharmaceuticals?

Dechra Pharmaceuticals paid dividends every year for the past 25 years.

What is the dividend of Dechra Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0.25 GBP are expected. This corresponds to a dividend yield of 0.65 %.

In which sector is Dechra Pharmaceuticals located?

Dechra Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Dechra Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Dechra Pharmaceuticals from 4/13/2023 amounting to 0.125 GBP, you needed to have the stock in your portfolio before the ex-date on 3/9/2023.

When did Dechra Pharmaceuticals pay the last dividend?

The last dividend was paid out on 4/13/2023.

What was the dividend of Dechra Pharmaceuticals in the year 2023?

In the year 2023, Dechra Pharmaceuticals distributed 0.449 GBP as dividends.

In which currency does Dechra Pharmaceuticals pay out the dividend?

The dividends of Dechra Pharmaceuticals are distributed in GBP.

Andere Kennzahlen von Dechra Pharmaceuticals

Our stock analysis for Dechra Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Dechra Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.